Dali Yan
Impact in
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
-
- Extracellular vesicles in disease
- Circular RNAs in diseases
- RNA modifications and cancer
- RNA Research and Splicing
- RNA Interference and Gene Delivery
Papers in
-
- MicroRNA in disease regulation 5
- Cancer-related molecular mechanisms research 5
- NF-κB Signaling Pathways 2
-
- RNA modifications and cancer 4
- Circular RNAs in diseases 3
- Co-authors
- Jifeng Feng (9 shared papers)Yong Hu (8 shared papers)Shaorong Yu (6 shared papers)Xiaobing Qin (4 shared papers)Siwen Liu (4 shared papers)Xiaoyue Xu (2 shared papers)Leilei Zhou (3 shared papers)Meiqi Shi (1 shared paper)
- Journals
- Oncotarget (3 papers)OncoTargets and Therapy (2 papers)Tumor Biology (2 papers)Bioscience Reports (1 paper)Gene (1 paper)
- Partner nations
- China
In The Last Decade
Dali Yan
14 papers receiving 502 citations
Peers
Comparison fields: 5 of 58
- Cancer Research 345
- Molecular Biology 390
- Oncology 99
- Immunology 37
- Immunology and Allergy 9
Countries citing papers authored by Dali Yan
This map shows the geographic impact of Dali Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dali Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dali Yan more than expected).
Fields of papers citing papers by Dali Yan
This network shows the impact of papers produced by Dali Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dali Yan. The network helps show where Dali Yan may publish in the future.
Co-authors
The 25 scholars most cited alongside Dali Yan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 209 | |
| 2 | 2017 | 74 | |
| 3 | 2016 | 57 | |
| 4 | 2017 | 26 | |
| 5 | 2016 | 23 | |
| 6 | 2016 | 19 | |
| 7 | 2017 | 16 | |
| 8 | 2017 | 16 | |
| 9 | 2017 | 16 | |
| 10 | 2017 | 15 | |
| 11 | 2017 | 14 | |
| 12 | 2017 | 14 | |
| 13 | 2017 | 2 | |
| 14 | 2021 | 2 |
About Dali Yan
Dali Yan is a scholar working on Cancer Research, Molecular Biology, Oncology, Surgery and Pulmonary and Respiratory Medicine, having authored 14 papers that have together received 503 indexed citations. Recurring topics across this work include MicroRNA in disease regulation (5 papers), Cancer-related molecular mechanisms research (5 papers), RNA modifications and cancer (4 papers), Circular RNAs in diseases (3 papers), NF-κB Signaling Pathways (2 papers), Drug Transport and Resistance Mechanisms (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (1 paper) and Cytokine Signaling Pathways and Interactions (1 paper). The work is most often cited by research in Cancer Research (345 citations), Molecular Biology (390 citations), Oncology (99 citations), Immunology (37 citations) and Immunology and Allergy (9 citations). Dali Yan has collaborated with scholars based in China. Frequent co-authors include Jifeng Feng, Yong Hu, Shaorong Yu, Xiaobing Qin, Siwen Liu, Xiaoyue Xu, Leilei Zhou, Meiqi Shi, Bo Shen and Dandan Wang. Their work appears in journals such as Oncotarget, OncoTargets and Therapy, Tumor Biology, Bioscience Reports and Gene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.